Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
Search Article 
Advanced search 
  Users Online: 904 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

    Article Cited by others


Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis

Kalra Sanjay, Sahay Rakesh, Gupta Yashdeep

Year : 2015| Volume: 19| Issue : 4 | Page no: 524-528

   This article has been cited by
1 Neuromodulatory effects of anti-diabetes medications: a mechanistic review
Habib Yaribeygi,Milad Ashrafizadeh,Neil C. Henney,Thozhukat Sathyapalan,Tannaz Jamialahmadi,Amirhossein Sahebkar
Pharmacological Research. 2019; : 104611
[Pubmed]  [Google Scholar] [DOI]
2 The Effect and Safety of Dapagliflozin in Patients with Type 2 Diabetes: A Single-Institution Pharmacovigilance Review
Hyung Woo Lee,Sun Joon Moon,Hee Sim Han,Eun Jeong Shin,Jin Hee Baek,Hyun-Joo Han,Young Min Cho,Kwi Suk Kim
The Journal of Korean Diabetes. 2017; 18(4): 275
[Pubmed]  [Google Scholar] [DOI]
3 Acid-base and electrolyte disorders associated with the use of antidiabetic drugs
Theodosios Filippatos,Eleftheria Tzavella,Christos Rizos,Moses Elisaf,George Liamis
Expert Opinion on Drug Safety. 2017; : 1
[Pubmed]  [Google Scholar] [DOI]
4 Effects of Sodium Glucose Cotransporter-2 Inhibitors on Serum Uric Acid in Type 2 Diabetes Mellitus
Hala Ahmadieh,Sami Azar
Diabetes Technology & Therapeutics. 2017;
[Pubmed]  [Google Scholar] [DOI]
5 Euglycemic ketosis in patients with type 2 diabetes on SGLT2-inhibitor therapy—an emerging problem and solutions offered by diabetes technology
A. Pfützner,D. Klonoff,L. Heinemann,N. Ejskjaer,J. Pickup
Endocrine. 2017; 56(1): 212
[Pubmed]  [Google Scholar] [DOI]
6 Complicaciones agudas hiperglucémicas e hipoglucémicas
I. Capel,I. Berges-Raso
Medicine - Programa de Formación Médica Continuada Acreditado. 2016; 12(18): 1035
[Pubmed]  [Google Scholar] [DOI]
7 Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Abd A. Tahrani,Anthony H. Barnett,Clifford J. Bailey
Nature Reviews Endocrinology. 2016;
[Pubmed]  [Google Scholar] [DOI]
8 Pharmacokinetic and pharmacodynamic drug evaluation of tofogliflozin for the treatment of type 2 diabetes
Kalliopi Pafili,Efstratios Maltezos,Nikolaos Papanas
Expert Opinion on Drug Metabolism & Toxicology. 2016; : 1
[Pubmed]  [Google Scholar] [DOI]
9 SGLT2 Inhibitors: Far Too Many Cautions and Alerts and Limited Efficacy
Udaya M Kabadi
Journal of Diabetes, Metabolic Disorders & Control. 2016; 3(5)
[Pubmed]  [Google Scholar] [DOI]
10 Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies
Vasilios Tsimihodimos,Theodosios D. Filippatos,Moses S. Elisaf
Expert Opinion on Drug Metabolism & Toxicology. 2016; : 1
[Pubmed]  [Google Scholar] [DOI]
11 Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials
Rizwana Parveen,Nidhi Bharal Agarwal,Neelam Kaushal,Ghanshyam Mali,Sheikh Raisuddin
Expert Opinion on Pharmacotherapy. 2016; 17(1): 105
[Pubmed]  [Google Scholar] [DOI]
12 Les pičges de l’acidocétose diabétique
S. Ayed,A. Bouguerba,P. Ahmed,J. Barchazs,M. Boukari,D. Goldgran-Toledano,C. Bornstain,F. Vincent
Réanimation. 2015; 24(6): 668
[Pubmed]  [Google Scholar] [DOI]
13 Sulfonylurea Glimepiride: A Proven Cost Effective, Safe and Reliable War Horse in Combating Hyperglycemia in Type 2 Diabetes
Udaya M. Kabadi
Journal of Diabetes Mellitus. 2015; 05(04): 211
[Pubmed]  [Google Scholar] [DOI]


Read this article